BMS Starts Nivolumab China Study Amid Rising Local Competition
This article was originally published in PharmAsia News
Executive Summary
Major US immuno-oncology player Bristol-Myers Squibb is racing to gain a nod for Opdivo in China, where a dozen or so companies are already developing PD-1 and PD-1 inhibitors, one of which has been out-licensed to Merck & Co.